Get access

Topiramate for Migraine Prophylaxis Among Chinese Population

Authors

  • Ho Lun Li MD,

  • Patrick Kwan MD,

  • Howan Leung MD,

  • Evelyn Yu MD,

  • Tak Hong Tsoi MD,

  • Andrew Che Fai Hui MD,

  • Bun Sheng MD,

  • Kwok Kwong Lau MD


  • From the Department of Medicine and Geriatrics, Princess Margaret Hospital, Hong Kong, China (Drs. Li, Sheng, and Lau); Division of Neurology, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China (Drs. Kwan, Leung, Yu, and Hui); Department of Medicine, Pamela Youde Nethersole Eastern Hospital, Hong Kong, China (Dr. Tsoi).

Address all correspondence to Dr. Ho Lun Li, Department of Medicine and Geriatrics, Princess Margaret Hospital, Kwai, Chung, Hong Kong, China.

Abstract

We evaluated the efficacy and safety of topiramate for migraine prophylaxis among Chinese patients in a multicenter prospective observational study. We found that topiramate at low doses was effective in preventing migraine headache in Chinese patients and was generally well tolerated. There was no difference in baseline headache frequency or intensity between responders and nonresponders.

Ancillary